Alestramustine

A chemotherapeutic agent

Alestramustine
File:Alestramustine.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Alestramustine is a chemotherapeutic agent that combines the properties of an alkylating agent and an estrogen. It is used in the treatment of prostate cancer.

Mechanism of action

Alestramustine is a prodrug that is metabolized into two active components: estradiol and nor-nitrogen mustard. The estradiol component allows the drug to target hormone-sensitive tissues, such as the prostate, while the nor-nitrogen mustard acts as an alkylating agent, interfering with DNA replication and cell division.

Pharmacokinetics

Upon administration, alestramustine is rapidly absorbed and converted into its active metabolites. The drug's distribution is influenced by its lipophilic nature, allowing it to penetrate cell membranes effectively. The metabolism of alestramustine primarily occurs in the liver, and its metabolites are excreted via the urinary system.

Clinical use

Alestramustine is primarily used in the treatment of advanced prostate cancer. It is particularly beneficial in cases where the cancer has become resistant to conventional hormone therapy. The drug's dual mechanism of action allows it to target cancer cells more effectively than traditional therapies.

Side effects

Common side effects of alestramustine include nausea, vomiting, and fatigue. Due to its estrogenic component, patients may also experience gynecomastia and fluid retention. Long-term use can lead to cardiovascular complications and thromboembolic events.

Related pages

• Prostate cancer
• Chemotherapy
• Alkylating agent
• Hormone therapy

Gallery

• Chemical structure of Alestramustine
  Chemical structure of Alestramustine